Aptevo Therapeutics offers up to $2.31M in stock

Offerings under the existing program are to be made only by means of the prospectus.

Available on EDGAR 11/02/2026 - 06:05 AM EST Accepted by SEC EDGAR 10/30/2026 - 06:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) filed a prospectus supplement for offers and sales of its common stock from time to time, with an aggregate offering price of up to $2,309,834, under its existing agreement with Roth Capital Partners, LLC, as sales agent. The shares are offered under the company’s effective Form S-3 registration statement, and offerings will be made only by means of the prospectus.

As of the prospectus supplement, Aptevo had issued and sold 303,157 shares under the agreement and prior prospectuses for $11.8 million in aggregate gross sale proceeds. The supplement further amends and supplements those earlier prospectus materials.

Filing Explained

The supplement sets an offer ceiling of $2,309,834, not a reported completed sale under this supplement; if Aptevo sells new shares under the existing at-the-market agreement, existing holders’ ownership percentages would fall absent offsetting changes.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Aggregate offering price: Up to $2,309,834 Shares issued and sold: 303,157 shares Aggregate gross sale proceeds: $11.8 million

3 metrics

Aggregate offering price Up to $2,309,834 Common stock offered and sold from time to time

Shares issued and sold 303,157 shares Under the Sales Agreement and prior prospectuses as of the prospectus supplement

Aggregate gross sale proceeds $11.8 million From shares issued and sold under the Sales Agreement and prior prospectuses

Key Terms

At The Market Offering Agreement, aggregate offering price, prospectus supplement, Registration Statement

4 terms

At The Market Offering Agreement financial

"under its existing At The Market Offering Agreement"

An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.

aggregate offering price financial

"having an aggregate offering price of up to $2,309,834"

The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.

prospectus supplement regulatory

"filed ... a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Registration Statement regulatory

"under the Company’s effective registration statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock is Aptevo (APVO) offering through its ATM program?

The prospectus supplement covers offers and sales of Aptevo common stock from time to time with an aggregate offering price of up to $2,309,834, under the existing agreement with Roth Capital Partners, LLC, as sales agent.

How many shares has APVO sold under its ATM agreement?

As of the prospectus supplement, Aptevo had issued and sold 303,157 shares under the Sales Agreement and prior prospectuses for aggregate gross sale proceeds of $11.8 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001671584false00016715842026-10-302026-10-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2026

APTEVO THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37746	81-1567056
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2401 4th Avenue Suite 1050
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		APVO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Filing of Prospectus Supplement

On October 30, 2026, Aptevo Therapeutics Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC’) a prospectus supplement (the “Prospectus Supplement” and collectively with the Prior Prospectus (as defined below), the “Prospectus”) under the Company’s effective registration statement on Form S-3 (the “Registration Statement”) (File No. 333-284969), relating to the offer and sale of the Company’s shares of common stock, par value $0.001 per share (“Common Stock”), from time to time having an aggregate offering price of up to $2,309,834 (the “Shares”), under its existing At The Market Offering Agreement, dated April 28, 2025 (the “Sales Agreement”), with Roth Capital Partners, LLC., as sales agent, which further amends and supplements the Company’s prospectus supplement filed with the SEC on April 28, 2025 and accompanying base prospectus (the “Original Prospectus”), as amended and supplemented by the Company’s prospectus supplement filed with the SEC on April 29, 2025 (collectively with the Original Prospectus, the “April 29, 2025 Prospectus”), May 22, 2025 (collectively with the April 29, 2025 Prospectus, the “May 22, 2025 Prospectus”) and June 20, 2025 (collectively with the May 22, 2025 Prospectus, the “Prior Prospectus”).

As of the date of the Prospectus Supplement, the Company had issued and sold 303,157 shares of Common Stock pursuant to the Sales Agreement and the Prior Prospectus for aggregate gross sale proceeds of $11.8 million.

Paul Hastings LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.

The offering of the Shares has been registered pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy the Shares described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being filed herewith:

Exhibit No.		Description
5.1		Opinion of Paul Hastings LLP
23.1		Consent of Paul Hastings LLP (contained in Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			APTEVO THERAPEUTICS INC.
Date:	November 2, 2026	By:	/s/ Daphne Taylor
			Daphne Taylor Senior Vice President and Chief Financial Officer

Filing Exhibits & Attachments

2 documents

Other Documents

• EX-5.1 EX-5.1 38.5 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB